CD274 and neoplasm: Enhanced tumour cytotoxicity interactions, making the tumour 'hot' and inflamed, may be achieved by combining two or more types of therapy, enhancing the immunogenicity of the TIME, increasing PD-L1 expression and activating natural killer cell engagement (Figure 2).